Loading
Phathom Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Topper James N, was filed 23 May 2025.
Phathom Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Phathom Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 21 October 2026, brought 21 filings signed by 7 insiders.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €6,141. One trade stands out by size: a sale of €6,141 from Breedlove Robert Charles, disclosed on 5 November 2025.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 21 filings here. Since 2021, the database holds 18 purchases and 49 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 175.1 m USD and net income at -221.2 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
139
Thresholds
n/a
Buy Volume
€1M
18 ops. · all time
Sell Volume
€34M
49 ops. · all time
Who traded when
BuySaleAsit Parikh3 buys
James N. Topper3 buys
Molly Henderson3 sales
Robert Charles Breedlove3 sales
Azmi Nabulsi2 sales
Frank Karbe1 buy
+1 other insider
Since the insiders bought
- +169.4%Entry US$4.12 · Close at T+365 US$11.10
- +289.2%Entry US$3.14 · Close at T+365 US$12.22
- +83.5%Entry US$8.37 · Close at T+365 US$15.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Phathom Pharmaceuticals, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$20.09.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.50
Analyst consensus
11 analystsStrong buy
US$10.00Target US$20.09(+168%)US$29.00
Income statement
RevenueUS$175.1M
Gross profitUS$152.5M87% margin
EBITDA-US$152.5M-87% margin
Net income-US$221.2M-41.3% margin
Valuation
PER (forward)7.0x
Beta0.50
Balance sheet & cash
Market capUS$606.8M
Total debtUS$211.8M
Free Cash Flow-US$167M
Profitability & ownership
ROA-8.8%
% insiders4.6%
% institutions94.4%
Last declaration on 8 October 2026
Declarations139 total
13,485 shares@ US$6.780.017% mcap100.0% of flowCommon StockSEC:0001193125-26-418114:0
460 shares@ US$9.050.0007% mcap6.7% of flowCommon StockSEC:0001193125-26-385250:0
1,555 shares@ US$11.0350.0030% mcap27.9% of flowCommon StockSEC:0001193125-26-306165:0
24,122 shares0Common StockSEC:0001193125-26-234566:0
24,122 shares0Common StockSEC:0001193125-26-234567:0
40,000 shares0Common StockSEC:0001193125-26-102632:0
13,000 shares0Common StockSEC:0001193125-26-088730:0
12,362 shares0Common StockSEC:0001193125-26-048867:0
3,461 shares0Common StockSEC:0001193125-26-048881:0
80,500 shares0Common StockSEC:0001193125-26-024600:0
776 shares@ US$13.6116.7% of flowCommon StockSEC:0001193125-26-021164:0
8,750 shares@ US$10.3012.0% of flowCommon StockSEC:0001193125-26-014187:0
251,034 shares0Common StockSEC:0001193125-26-001127:0
75,345 shares0Common StockSEC:0001193125-26-001125:0
82,715 shares0Common StockSEC:0001193125-26-001123:0
8,750 shares@ US$10.3011.9% of flowCommon StockSEC:0001193125-25-331104:0
62,038 shares0Common StockSEC:0001193125-25-327126:0
230 shares@ US$16.285.9% of flowCommon StockSEC:0001193125-25-327135:0
17,370 shares0Common StockSEC:0001193125-25-327131:0
90,000 shares0Common StockSEC:0001193125-25-305575:0
524 shares@ US$13.5111.4% of flowCommon StockSEC:0001193125-25-267057:0
144,000 shares0Common StockSEC:0001193125-25-234650:0
90,000 shares0Common StockSEC:0001193125-25-220950:0
461 shares@ US$12.098.9% of flowCommon StockSEC:0000950170-25-113822:0
1,692 shares@ US$8.363922.5% of flowCommon StockSEC:0000950170-25-096917:0
25 of 139 declarations
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company focuses on acid-related gastrointestinal disorders, making it a specialty pharma name rather than a broad diversified healthcare group. Phathom was launched in 2019 through a collaboration between Takeda Pharmaceutical and Frazier Healthcare Partners, with the aim of building a company dedicated to the development and commercialization of novel GI therapies. Its headquarters are in New Jersey, and its operating model is largely centered on the U.S. market, where it is building a commercial franchise around its lead asset.
The company’s core product platform is VOQUEZNA, a vonoprazan-based franchise designed for the treatment of gastroesophageal reflux disease and related acid-mediated conditions. Phathom markets VOQUEZNA tablets, as well as VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which are used in H. pylori eradication regimens. From an investment perspective, this gives Phathom a differentiated position in a large and clinically meaningful GI market, with a product set that is protected by intellectual property and supported by a distinct mechanism of action. In a competitive landscape that includes large pharmaceutical companies and established generic therapies, Phathom’s edge comes from innovation, product labeling, and the commercial adoption of a novel acid-suppression platform.
Read moreShow less
Commercial execution has become the key storyline. Recent company disclosures show that prescription growth accelerated through 2025, with more than 580,000 filled prescriptions for the VOQUEZNA franchise through late July 2025 and more than one million cumulative prescriptions in the United States by the fourth quarter of 2025. Those milestones indicate that Phathom has moved beyond launch phase and into a more visible commercialization stage. At the same time, the company remains a specialty pharma growth story with the usual risks: reliance on a limited product portfolio, the need to maintain physician awareness and payer access, and the pressure to fund sales and marketing while continuing to scale revenue.
Phathom’s strategic relevance for investors lies in the combination of a focused GI franchise, a U.S.-only commercial emphasis, and a product that is still early in its adoption curve. The company is not a broad healthcare platform; it is a concentrated bet on whether VOQUEZNA can become a durable commercial standard in acid-related GI disease in the United States. For French-speaking investors in France, Belgium, and Switzerland, the case is best viewed as a U.S. NASDAQ specialty pharma story with meaningful upside tied to execution, uptake, and reimbursement dynamics rather than to a diversified portfolio of assets.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
